Endogenex Announces Publication of REGENT-1 Clinical Study Results in Diabetes, Obesity and MetabolismPeer-Reviewed Data Show Durable HbA1c Reduction, Significant Weight Loss, and a Favorable Safety Profile Through 48 Weeks Following a Single Endoscopic Procedure for Type 2 Diabetes
Endogenex to Present Data on Endoscopic Procedure for Type 2 Diabetes at American Diabetes Association’s (ADA) 85th Scientific SessionsMINNEAPOLIS, June 17, 2025 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), will present results from its REGENT-1 Australia clinical study at the American Diabetes Association’s (ADA) 85th Scientific Sessions, taking place in Chicago, June 20 – 23, 2025.
Endogenex Highlights 48-Week REGENT-1 Clinical Study Results at Digestive Disease Week 2025Novel Endoscopic Procedure Demonstrates Substantial and Durable Reduction in Insulin Resistance and Improvement in Beta Cell Function for People with Type 2 Diabetes
